Humacyte (HUMA) Net Income towards Common Stockholders (2020 - 2026)
Humacyte (HUMA) reported Net Income towards Common Stockholders of -$30.9 million for Q1 2026, down 20.9% year-over-year from -$39.0 million in Q1 2025, and up 7.63% quarter-over-quarter from -$33.4 million in Q4 2025.
Humacyte (HUMA) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$30.9 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$30.9 million, down 20.9% year-over-year; the trailing twelve-month figure through Mar 2026 was -$122.2 million (down 3.73% YoY), and the FY2025 annual result was -$116.8 million, up 2.32% from the prior year.
- Net Income towards Common Stockholders advanced to -$30.9 million in Q1 2026 per HUMA's latest filing, from -$33.4 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$19.7 million in Q2 2022 and troughed at -$33.4 million in Q4 2025.
- A 5-year average of -$26.9 million and a median of -$26.8 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders sank 36.74% in 2023, then rose 16.84% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$21.0 million in 2022, then fell by 27.23% to -$26.8 million in 2023, then retreated by 11.18% to -$29.8 million in 2024, then declined by 12.33% to -$33.4 million in 2025, then grew by 7.63% to -$30.9 million in 2026.
- Business Quant data shows HUMA's Net Income towards Common Stockholders at -$30.9 million in Q1 2026, -$33.4 million in Q4 2025, and -$26.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -56.48 Mn |
| 10 | Humacyte | 267.09 Mn | 218.55 Mn | -1.54 Mn | -30.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.88 Mn |
| Dec 31, 2025 | -33.43 Mn |
| Sep 30, 2025 | -26.41 Mn |
| Jun 30, 2025 | -31.44 Mn |
| Mar 31, 2025 | -25.54 Mn |
| Dec 31, 2024 | -29.76 Mn |
| Sep 30, 2024 | -31.76 Mn |
| Jun 30, 2024 | -30.70 Mn |
| Mar 31, 2024 | -27.36 Mn |
| Dec 31, 2023 | -26.77 Mn |
| Sep 30, 2023 | -24.72 Mn |
| Jun 30, 2023 | -26.96 Mn |
| Mar 31, 2023 | -22.74 Mn |
| Dec 31, 2022 | -21.04 Mn |
| Sep 30, 2022 | -24.25 Mn |
| Jun 30, 2022 | -19.72 Mn |
| Mar 31, 2022 | -23.16 Mn |
| Dec 31, 2021 | -23.01 Mn |
| Sep 30, 2021 | -21.74 Mn |
| Jun 30, 2021 | -20.48 Mn |